Allarity Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 30, 2022 |
|---|---|---|---|---|---|
| Revenue | $320,000 | $0 | — | — | — |
| Gross profit | — | — | — | -$2.3M | — |
| Operating income | -$12.6M | -$27.2M | -$17.1M | -$34.5M | — |
| Operating expenses | $12.9M | $27.2M | $17.1M | $34.5M | — |
| Cash from operations | -$14.8M | -$17.4M | -$12.7M | -$16.8M | — |
| Capital expenditure | $8,000 | $298,000 | $0 | $18,000 | — |
| Free cash flow | -$14.8M | -$17.6M | -$12.7M | -$16.8M | — |
| Share repurchases | $3.2M | $0 | — | — | — |
| Impairments | $0 | $9.7M | $0 | $3.6M | — |
| Total assets | $18.3M | $22.6M | $11.9M | $14.5M | — |
| Total liabilities | $8.4M | $10.8M | $14.6M | $12.7M | — |
| Total debt | — | — | — | $2.7M | $650,000 |
Shares outstanding 15.9M · Free float 46.9%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.